Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population

Mojumdar, Kamalika; Vajpayee, Madhu; Chauhan, Neeraj K.; Mendiratta, Sanjay
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p416
Academic Journal
Background: Timely access to antiretroviral therapy is a key to controlling HIV infection. Late diagnosis and presentation to care diminish the benefits of antiretrovirals and increase risk of transmission. We aimed to identify late presenters in patients sent for first CD4 T cell count after HIV diagnosis, for therapy initiation evaluation. Further we aimed at identifying patient factors associated with higher risk of late presentation. Methods: Retrospective data collection and analysis was done for 3680 subjects visiting the laboratory for CD4 T cell counts between 2001 and 2007. We segregated the patients on basis of their CD4 T cell counts after first HIV diagnosis. Factors associated with risk of late presentation to CD4 T cell counts after HIV diagnosis were identified using univariate analysis, and the strength of association of individual factor was assessed by calculation of odds ratios. Results: Of 3680 subjects, 2936 (83.37%) were defined as late presenters. Late testing varied among age groups, transmission categories, and gender. Males were twice as likely to present late as compared to females. We found significant positive association of heterosexual transmission route (p < 0.001), and older age groups of 45 years and above (p = 0.0004) to late presentation. Female sex, children below 14 years of age and sexual contact with HIV positive spouse were associated with significantly lower risks to presenting late. Intravenous drug users were also associated with lower risks of late presentation, in comparison to heterosexual transmission route. Conclusions: The study identifies HIV infected population groups at a higher risk of late presentation to care and treatment. The risk factors identified to be associated with late presentation should be utilised in formulating targeted public health interventions in order to improve early HIV diagnosis.


Related Articles

  • Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. Losina, Elena; Touré, Hapsatou; Uhler, Lauren M.; Anglaret, Xavier; Paltiel, A. David; Balestre, Eric; Walensky, Rochelle P.; Messou, Eugène; Weinstein, Milton C.; Dabis, François; Freedberg, Kenneth A. // PLoS Medicine;Oct2009, Vol. 6 Issue 10, p1 

    Background: Data from HIV treatment programs in resource-limited settings show extensive rates of loss to follow-up (LTFU) ranging from 5% to 40% within 6 mo of antiretroviral therapy (ART) initiation. Our objective was to project the clinical impact and cost-effectiveness of interventions to...

  • Perspectives on HAART: switch maintenance therapy. Leen, C. L. S. // International Journal of STD & AIDS;Sep2003, Vol. 14 Issue 9, p577 

    Switch studies have been carried out to explore changes in side effects in adherence. Discontinuing the protease inhibitor (PI) component of highly active antiretroviral therapy (HAART) regimen is often associated with improved adherence and improved quality of life. Following switching from a...

  • Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Boullie, A.; Ford, N. // Sexually Transmitted Infections;Dec2007, Vol. 83 Issue 8, p503 

    The article comments on the need for cost-effective interventions to reduce HIV in developing countries. There have been concerns on the promotion of widespread access to antiretroviral therapy in Southern Africa. Data on the effectiveness of the interventions since year 2000 have been compiled....

  • Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability. Kimmel, April D.; Resch, Stephen C.; Anglaret, Xavier; Daniels, Norman; Goldie, Sue J.; Danel, Christine; Wong, Angela Y.; Freedberg, Kenneth A.; Weinstein, Milton C. // Cost Effectiveness & Resource Allocation;2012, Vol. 10 Issue 1, p12 

    Background: In resource-limited settings, HIV budgets are flattening or decreasing. A policy of discontinuing antiretroviral therapy (ART) after HIV treatment failure was modeled to highlight trade-offs among competing policy goals of optimizing individual and population health outcomes....

  • Chronic HIV Infection: Can Anyone Afford a Drug Holiday? Kane, Brigid // Annals of Internal Medicine;8/20/2002, Vol. 137 Issue 4, p301 

    Discusses the management strategies for HIV infections and AIDS. Consequences of repeated interruptions of successful antiretroviral therapy in chronically infected patients; Definitive autovaccination trial in patients with chronic HIV infection; Feasibility of interrupting antiretroviral...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Jan2010, Vol. 24 Issue 1, p65 

    The article offers news briefs related to antiviral agents used in the treatment of HIV infections in the U.S. On December 1, 2009, the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents were revised. A research conducted in Rwanda has established that the...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Aug99, Vol. 13 Issue 8, p503 

    Presents news briefs concerning antiviral therapy for patients with human immuno deficiency syndrome (HIV) and acquired immune deficiency syndrome (AIDS). Proposal for Highly Active Antiretroviral Therapy (HAART) to be used as induction therapy; Study showing college-educated patients who...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Aug2000, Vol. 14 Issue 8, p453 

    Features several medical news briefs related to the treatment and management of HIV/AIDS infection as of August 2000. Reduction of treatment toxicity through drug holidays; Vaccines for HIV-infected patients; HIV screening among pregnant women; Drug resistance testing for non-compliant HIV/AIDS...

  • Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel. Yeni, Patrick G.; Hammer, Scott M.; Carpenter, Charles C. J.; Cooper, David A.; Fischl, Margaret A.; Gatell, Jose M.; Gazzard, Brian G.; Hirsch, Martin S.; Jacobsen, Donna M.; Katzenstein, David A.; Montaner, Julio S. G.; Richman, Douglas D.; Saag, Michael S.; Schechter, Mauro; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Volberding, Paul A. // JAMA: Journal of the American Medical Association;7/10/2002, Vol. 288 Issue 2, p222 

    Objective: New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start, what drugs to start with, when to change, and what to change to. These updated recommendations are intended to guide practicing physicians actively involved in human...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics